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Abstract
Background: Several intervention studies have demonstrated that exercise training has beneficial effects among
cancer patients. However, older cancer patients are underrepresented in clinical trials, and only few exercise-based
studies have focused specifically on older patients with cancer. In particular, research investigating the effects of
exercise training among older patients with advanced cancer is lacking. The purpose of the current study is to
investigate the effect of a 12-week multimodal and exercise-based intervention among older patients (≥65 years)
with advanced pancreatic, biliary tract or lung cancer, who are treated with first-line palliative chemotherapy,
immunotherapy or targeted therapy.
Methods: PACE-Mobil-PBL is a two-armed randomized controlled trial. Participants will be randomized 1:1 to an
intervention group (N = 50) or a control group (N = 50). Participants in the intervention group will receive standard
oncological treatment and a 12-week multimodal intervention, comprised of: (I) supervised exercise training, twice
weekly in the hospital setting, (II) home-based walking with step counts and goal-setting, (III) supportive and
motivational nurse-led counseling, and (IV) protein supplement after each supervised training session. Participants in
the control group will receive standard oncological treatment. The primary outcome is physical function measured
by the 30-s chair stand test. Secondary outcomes include measures of feasibility, activity level, physical capacity and
strength, symptom burden, quality of life, toxicity to treatment, dose reductions, inflammatory biomarkers, body
weight and composition, hospitalizations and survival. Assessments will be conducted at baseline, and after 6, 12
and 16 weeks.
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Discussion: The current study is one of the first to investigate the effect of an exercise-based intervention
specifically targeting older patients with advanced cancer. PACE-Mobil-PBL supports the development of health
promoting guidelines for older patients with cancer, and the study results will provide new and valuable
knowledge in this understudied field.
Trial registration: The study was prospectively registered at ClinicalTrials.gov on January 26, 2018 (ID: NCT03411200).
Keywords: Advanced cancer, Biliary tract cancer, Cancer, Counseling, Exercise, Lung cancer, Mobilization, Multimodal
intervention, Older, Pancreatic cancer, Physical activity
Background
Advanced age is the leading risk factor for development of
cancer overall, and approximately 60% of all cancers in
Europe and in the USA are diagnosed among patients aged
65 years or older [1, 2]. Although the risk of cancer in-
creases with age, and the number of older patients with
cancer is expected to rise in the coming years [3, 4], re-
search on older patients with cancer is limited [1, 4]. Aging
involves a continuum of changes in function, biological,
psychological, and social structures that vary depending on
individual differences. In a biological view, aging causes
changes in the organism that lead to a decline in organ
functions and in physiological reserves [5–8]. Comorbidity,
defined as the occurrence of two or more medically diag-
nosed diseases, increases with age and heightens the risk of
disability and mortality [9, 10]. In addition, use of multiple
drugs for multiple diseases, also known as polypharmacy,
leads to an increased risk of drug interactions, adverse reac-
tions and poor adherence [11].
Cancer and aging
Aging itself is associated with limitations in physical func-
tion and reduced reserve capacity. A diagnosis of cancer
and its accompanying treatments can lead to numerous
symptoms and side effects, physical disability, psycho-
logical distress and increased health care needs [12]. The
interplay between age-related and cancer-related declines
in health increases vulnerability and risk of development
of short- and long-term disabilities [13, 14]. Older patients
with cancer have a higher incidence of limitations in activ-
ities of daily living (ADL), reduced quality of life (QoL),
and a higher prevalence of geriatric syndromes such as de-
pression, falls and osteoporosis compared to older adults
without a history of cancer [15, 16]. Research suggests that
older patients with cancer benefit from chemotherapy
similar to younger patients [17, 18]. However, older pa-
tients with cancer are at increased risk of toxicity due to
age-related physiological changes [19].
Sarcopenia and cachexia
Loss of muscle mass and strength is a part of the nor-
mal aging process and is referred to as primary sarco-
penia [20]. Sarcopenia has multiple contributing factors
including aging itself, insufficient nutrition, sedentary
lifestyle or bedrest. The term secondary sarcopenia is
often used to describe sarcopenia that is caused by
other factors such as cancer or other chronic diseases
[20]. Cachexia is another depleting syndrome that
causes weight loss and muscle wasting due to an under-
lying disease [21]. The pathophysiology of cancer cachexia
includes a complex combination of reduced energy
intake and uptake, hormonal alterations, abnormal me-
tabolism and inflammation [21]. Previous studies have
identified cachexia and sarcopenia as contributors to
impaired physical functioning [22], reduced tolerance
to anti-cancer treatment [23, 24], higher symptom bur-
den [25], reduced QoL [25, 26] and increased mortality
[24, 27, 28] among patients with cancer.
Exercise training
Research has shown that exercise training (e.g. aerobic
training, resistance training, and balance and flexibility ex-
ercises) is safe and beneficial for older people [29–31].
Documented effects include increased muscle mass and
strength, functional mobility and ADL function, im-
proved QoL, and reduction of falls and depressive
symptoms [29–32]. The effect of exercise training has
also been widely investigated in cancer patients [33–35].
A myriad of beneficial effects of exercise training have
been documented, including reduced severity of cancer
and treatment-related symptoms and side effects, as
well as improved aerobic capacity, muscle strength,
physical functioning and QoL [33–36]. However, older
patients are underrepresented in clinical trials, and only
few exercise-based intervention studies have focused
specifically on older patients with cancer [37]. Among
the few studies that have investigated the effect of exer-
cise training in older patients with cancer, most have
focused on older patients with early-stage breast, pros-
tate and colorectal cancer. Especially, research investi-
gating the effect of exercise training in older patients
with advanced cancer is lacking [37].
Pancreatic, biliary tract and lung cancer
With median ages around 65 to 70 years at diagnosis,
pancreatic cancer (PC), biliary tract cancer (BTC) and
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lung cancer (LC) are malignancies highly associated with
aging. These cancers are most often diagnosed at an ad-
vanced stage, and therefore the majority of patients are
treated with palliative therapies. Focusing on LC, several
previous studies have provided evidence that exercise
training is feasible, safe and beneficial for patients with LC
before, during and after anti-cancer treatment [38–41].
Demonstrated effects include reduced surgical complica-
tions, reduced levels of symptoms and side effects, and
improvements in physical function and capacity [38–41].
Only one prior exercise-based study has focused specific-
ally on older patients with LC. In this study, Lai et al. [42]
investigated the effect of a short-term preoperative pul-
monary rehabilitation program in 60 older patients
(≥70 years) with non-small cell LC (NSCLC) scheduled to
lobectomy, and demonstrated significant improvements in
functional capacity and peak expiratory flow, as well as re-
ductions in length of hospital stay and post-operative
complications. Exercise training for patients with PC and
BTC is a relatively unexplored research field. In a random-
ized controlled trial, Yeo et al. [43] investigated the effect
of a 12-week home-based walking program in 102 patients
with resected PC or periampullary cancer. After study
completion, patients in the intervention group were walk-
ing twice as far as patients in the control group, and had
significant reductions in pain and fatigue, as well as im-
proved self-reported physical functioning [43]. In a pilot
study from 2014, Jensen et al. [44] investigated the feasi-
bility of exercise training in 26 patients with advanced
gastrointestinal cancers undergoing palliative chemo-
therapy. Patients were randomized to one of two groups;
resistance training or aerobic exercise on a bicycle ergom-
eter for 12 weeks. In both groups, a significantly de-
creased level of fatigue was demonstrated from pre to
post-assessment, and sleep quality was also significantly
improved. However, only minor improvements were
seen in a few domains of QoL measures, and no im-
provements were demonstrated in nausea/vomiting,
constipation, dyspnea or appetite/anorexia [44]. No
prior studies have investigated the effect of an exercise
program specifically for older patients with PC or BTC.
Aim
The aim of the current study is to investigate the effect of
a 12-week multimodal and exercise-based intervention in
older patients newly diagnosed with advanced PC, BTC or
LC who are undergoing first-line palliative chemotherapy,
immunotherapy or targeted therapy.
Hypothesis
We hypothesize that with a multimodal and exercise-based
intervention, participants will maintain physical function.
In addition, we believe that participants in the intervention
group will have reductions in symptoms and side effects,
improved QoL and psychological wellbeing, limited weight
loss and muscle wasting, and increased treatment tolerance,
compared to participants in the control group.
Methods
Design
PACE-Mobil-PBL is a prospective two-armed random-
ized controlled trial. The study is planned to include 100
patients with advanced PC, BTC or LC, who are treated
with first-line palliative chemotherapy, immunotherapy
or targeted therapy at the Department of Oncology at
Copenhagen University Hospital, Herlev and Gentofte,
Denmark. The overall study design is illustrated in Fig. 1.
This article describes the design of the study and complies
with the SPIRIT guidelines for randomized controlled trial
protocols, and with the Consensus on Exercise Reporting
Template (CERT) recommendations for reporting exercise
programs in clinical trials [45].
Participants
Patients are eligible for inclusion if the following criteria are
fulfilled: 1) diagnosis with locally advanced or metastatic
PC, BTC or NSCLC within 12 weeks; 2) unresectable
cancer; 3) treatment with first-line palliative chemotherapy,
immunotherapy or targeted therapy; 4) age ≥ 65 years; 5)
Eastern Cooperative Oncology Group (ECOG) perform-
ance status score ≤ 2; 6) ability to speak and read Danish,
and to provide a signed informed consent form (ICF).
Exclusion criteria are: 1) any physical condition that hin-
ders the execution of physical exercise training; 2)
small-cell LC; 3) documented and uncontrolled brain
metastases that hinder study participation based on the
referring oncologist’s assessment; 4) dementia, psychotic
disorders or cognitive diseases or conditions that hinder
participation in an exercise-based clinical trial; 5) unstable
medical disease or a history of serious or concurrent
illness (any medical condition that might be aggravated by
exercise training or that cannot be controlled). Patients
with documented bone metastases will be excluded from
participation if they have a bone metastatic burden or
location that poses a risk of pathologic fractures in the
performance of exercise training, as assessed by the refer-
ring oncologist.
After the initial screening procedure, the research team
will obtain ICF and collect all relevant baseline data before
randomization.
Patient involvement
With the aim of involving patients in the research process,
individual semi-structured interviews were conducted in
older patients with advanced PC, BTC and LC, before the
final intervention program was developed. The aim of
these pre-interviews was to gain insight into how patients
experience and manage symptoms and side effects, to
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explore their views on exercise training during oncological
treatment, and to get their expert advice on the optimal
recruitment procedure, intervention composition, and on
relevant outcome measures (unpublished results).
Randomization
After inclusion and baseline assessments, participants
are randomly allocated to the intervention group or the
control group using a 1:1 block randomization. The
block size will only be known by the statistician carry-
ing out the randomization procedure. Randomization will
be stratified on diagnosis by using separate randomization
lists for each diagnosis group (PC, BTC and LC). The
‘blockrand’ package of the statistical software R was used
to generate all randomization lists. Randomization will be
administered via the web-based research platform RED-
Cap (Research Electronic Data Capture). Source codes to
generate all randomization lists are stored to ensure full
reproducibility.
Intervention
Participants in the intervention group will receive stand-
ard oncological treatment and a 12-week multimodal
exercise-based intervention comprised of the four follow-
ing components:
#1: Supervised and group-based exercise training at the
hospital setting; two times a week for sessions of
approximately 60 min. The program consists of
warm-up exercises of light to moderate intensity,
including exercises for balance and flexibility, and a
program of progressive resistance training (PRT)
that comprises seven resistance training exercises
targeting the large muscle groups. In the first two
weeks, participants will be introduced to the PRT
program, starting with high repetition numbers
and low loads. During the intervention period, the
volume of the PRT will progress from two to three
sets, and the load will increase from 15 to 10
repetitions maximum (yielding a heavier load
relative to each participant’s maximum). The
progression will be tailored to each individual
participant. Three experienced physiotherapists
(range 6–17 years) will supervise all training
sessions. Training sessions will be performed in
groups of up to 12 participants at the rehabilitation
facilities at Herlev and Gentofte Hospital, where
appropriate strength training equipment is available
(Technogym Element series, Gambettola, Italy). For
detailed description of the supervised exercise
program see Table 1.
Fig. 1 PACE-Mobil-PBL study design. Abbreviations: BTC (biliary tract cancer), LC (lung cancer), PC (pancreatic cancer)
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#2: Nutritional supplement after supervised exercise
training; to prevent a negative energy balance on
training days, a protein supplement (e.g. protein
drink or bar, 227–300 cal and 12–20 g protein) will
be served for participants after each training
session.
#3: An individualized activity program with steps
counts, goal-setting and evaluation; based on each
participant’s starting point, preferences and
motivation, an individualized activity program will
be conducted with the overall aim of maintaining or
increasing the level of daily activity. The level of
activity will be measured as steps counts with a
Garmin Vivofit 3 activity tracker (Garmin, Olathe,
Kansas, U.S.). Goal-setting and evaluation in
relation to walked steps will be conducted once
weekly, face-to-face or by telephone, in collaboration
between each participant and a member of the
research team.
#4: Motivational and supportive counseling; participants
in the intervention group will participate in two
sessions of individualized nurse-led counseling. The
first session will be held immediately after study
entry, and the second will be conducted after
6 weeks. Counseling will be based on a holistic
assessment of each participant’s life situation and
potential challenges. Each participant will be asked
about potential problems in different life domains
(physical, functional, psychological/emotional,
social, and existential/spiritual). Based on identified
needs, participants will be challenged with questions
about the characteristics of the problem(s), factors
that may influence the problem(s), and their
problem management strategy. The purpose of
this process is to activate the participants and to
promote self-management. Also, advice and
counseling on identified problems will be provided,
and followed up if needed. If participants present
any complex medical problems, they will be
encouraged to contact their oncologist or general
practitioner, as appropriate. As mandatory
components, all participants will be informed
about expected bodily reactions to exercise training,
and advised about sufficient nutrition during the
intervention. If participants need specialized
nutritional counseling, they will be referred to a
dietician.
Controls
Participants in the control group will receive standard
oncological treatment. No restrictions on physical activ-
ity are made for control participants.
Study outcome measures
The primary endpoint is the between-group difference in
within-group changes in physical capacity and lower ex-
tremity strength measured with the 30-s chair stand test
(30s-CST) at the post-intervention assessment. Secondary
endpoints include feasibility measures, adverse events,
and changes in functional performance, muscle strength,
body composition, body weight, patient-reported perform-
ance status, symptom burden, symptoms of depression
and anxiety, QoL, physical activity, treatment tolerance
and toxicity, inflammatory biomarkers, hospital admis-
sions and mortality. The outcome measures for both
groups are described in the following section.
Physical tests
To measure physical function and lower extremity strength,
the 30s-CST will be used (primary outcome) [46]. The
30s-CST is considered as highly relevant for older patients
with cancer, as the ability to rise from a chair is regarded a
prerequisite for functional independence. The 30s-CST is a
widely used and validated physical measure, especially
among older people, and it has also been used and tested
among patients with cancer [47–49]. Physical performance
will also be assessed with a 6 and 10-m gait speed test. Gait
speed is a suitable measure to use in a clinical rehabilitation
setting, and has a documented predictive value for func-
tional and cognitive decline, falls, independence, and mor-
tality [50, 51]. To measure physical capacity and endurance,
the six-minute-walk test (6MWT) will be used [46]. The
6MWT measures the distance an individual is able to walk
over a total of six minutes on a hard and flat surface. The
Table 1 Description of the supervised exercise program
Duration of exercise
program
12 weeks (24 sessions)
Duration of exercise
sessions
60 min (10 min of warm-up, 45 min of PRT
and 5 min of stretching)
Exercise frequency 2 times a week
Rest period between
exercise sessions
2–5 days
Warm-up Exercises of light to moderate intensity with
elements of balance and flexibility training
(e.g. walking around in circles with changing
directions, walking on toes and heels, floor
touch, walking lunges, exercises on balance
board)
Description of PRT
exercises
Chest press, abdominal crunch, leg press, leg
curl (hamstrings), leg extension (quadriceps),
lower back and low row
No. of repetitions
(PRT)
15 RM (session 1–2), 12 RM (session 3–13),
10 RM (session 14–24)
No. of sets per session
(PRT)
2 (session 1–6), 3 (session 7–24)
Rest period between
sets (PRT)
60 s
Abbreviations: No. (number), PRT progressive resistance training, RM
repetition maximum
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test was originally developed for use in frail older patients,
but has been used and validated in a variety of different
populations [52, 53]. To measure physical function and
strength of the upper body, the handgrip strength test will
be used [54]. Research has shown that handgrip strength
may be independently associated with functional capacity,
QoL and survival in patients with advanced cancer [55].
Detailed descriptions of the performance of physical tests
can be found in an additional file (see Additional file 1).
Feasibility measures
Feasibility of the intervention will be evaluated as ac-
ceptability, attrition and adherence. Acceptability will be
measured as the number of eligible patients who agree
to participate in the study. Reasons for declining study
participation will be listed and evaluated. Attrition will
be registered as the number and percentage of partici-
pants who do not complete the study requirements. For
each component of the intervention adherence will be
assessed as the percentage of study parts completed.
Data on adverse events related to the intervention will
be monitored according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, ver-
sion 4.0 (NCI CTCAE v4.0).
Patient-Reported Outcome Measures (PROM)
Patient-reported performance status (PRPS) will be
assessed using the ECOG performance status [56]. To
measure symptom burden, the M.D. Anderson Symp-
tom Inventory (MDASI) version 1 will be used [57].
MDASI is a multi-symptom PROM assessing the sever-
ity of symptoms and their interference with daily living
[57]. To assess QoL, the European Organisation for Re-
search and Treatment of Cancer Quality of Life Ques-
tionnaire C30 (EORTC QLQ-C30) version 3.0 will be
applied [58]. The EORTC-QLQ-C30 is designed to be
cancer specific, and consists of 30 items distributed
throughout different functional and symptom scales
[58]. To assess symptoms of depression and anxiety,
the Hospital Anxiety and Depression Scale (HADS)
version 3.0 will be used [59]. HADS comprises 14 items
and is designed to measure general depression and anx-
iety by self-administration [59].
Physical activity
Level of physical activity will be measured by step counts
using a Garmin Vivofit 3 activity tracker (Garmin, Olathe,
Kansas, U.S.). The average number of steps walked mea-
sured over three consecutive days will be used as an esti-
mate of physical activity.
Qualitative assessment of participants’ experiences
Qualitative semi-structured interviews will be conducted
with a sample of participants from the intervention
group post intervention to explore participants’ experi-
ences and satisfaction with the intervention.
Treatment tolerance and toxicity
Data on dose-reductions and treatment discontinuations
will be registered prospectively throughout the interven-
tion period. Toxicity will be registered according to the
NCI CTCAE v4.0.
Body measures
Weight, height and body mass index (BMI) will be
assessed using standard procedures (no shoes, light cloth-
ing). Body composition will be assessed by whole-body
dual-energy x-ray absorptiometry (DXA) scan (GE lunar
iDXA, GE Healthcare Technologies, Madison, Wisconsin,
U.S.), and by bioelectrical impedance (BI) assessment
(Body Composition Monitor, Fresenius Medical Care, Bad
Homburg v.d.H., Germany).
Inflammatory biomarkers
To explore the influence of exercise training on inflam-
mation, data on inflammatory biomarkers C-reactive
protein (CRP), interleukin 6 (IL-6), and Chitinase-3-like
protein 1 (CHI3L1), also known as YKL-40, will be
collected from medical records or through cooperative
research projects.
Hospital admissions
Data on number, causes, and length of hospitalization
during the study period will be collected from medical
records.
Mortality/survival
Incidences of deaths and causes of deaths will be regis-
tered throughout the study period by review of medical
records.
Frequency and timing of study assessments are shown
in Table 2. REDCap will continuously be used for data
entry during the study period, and subsequently for data
storage.
Blinding procedures
Assessments of the primary outcome 30s-CST and all
other physical tests will be performed by blinded physio-
therapists. Due to the nature of the study, study partici-
pants are not blinded.
Statistics
Sample size
No prior studies have investigated the clinically import-
ant difference in the 30s-CST in patients with cancer.
According to a previous study focusing on patients with
osteoarthritis, the clinically important change in the
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30s-CST was set at 2.6 repetitions [60]. Based on re-
sults from prior studies in patients with advanced can-
cer, a standard deviation (SD) of approximately 3 has
been reported [61, 62]. To be able to detect a
between-group difference in the within-group changes
of 2.6 repetitions in the 30s-CST, and to obtain a type I
error rate of 5% and a power of 90%, a sample size of
29 participants per study arm will be needed. To ac-
count for a dropout rate of approximately 40%, it has
been decided to increase the group size to 50. Thus, a
total of 100 participants will be included in the trial.
Analyses
Feasibility measures will be reported as numbers and
percentages. Baseline characteristics will be calculated
for all participants (total), and separately for the inter-
vention and control group. For all quantitative variables
the median number and interquartile range (IQR) will
be calculated, and for nominal variables the number and
percentage distribution will be calculated. Results from
physical tests, blood test, body measures, questionnaires,
hospitalizations and toxicity-measures will be reported
as means and SDs or as median and IQR, as appropriate.
Table 2 Schedule of study assessments
Time (week no.) -2 to 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 17
Enrollment
Eligibility screen X
Informed consent X
Randomization X
Intervention X---------------------------------------------------------------------------------------------------------------------------X
Physical tests and examinations
30s-CST (primary outcome) X X X X
6MWT X X X X
Handgrip strength X X X X
Gait speed test X X X X
Physical activitya X X
DXA X X
BI X X
Body weighta X X X X
Inflammatory biomarkers X X X X
PROMs
PRPS X X X X
MDASIa X X X X
EORTC-QLQ-C30 X X X X
HADS X X X X
Qualitative exploration
Individual Interviews X
Feasibility
Adherence X X X X X X X X X X X X X X
Attrition X X X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X
Oncological treatment
Treatment related toxicityb X X X X X X X X X X X X X X X X
Dose-reductionsb X X X X X X X X X X X X X X X X
Hospitalizations X X X X X X X X X X X X X X X X
Survival X X X X X X X X X X X X X X X X
aOnce weekly for participants in the intervention group bRegistered for every treatment course
Abbreviations: 30s-CST 30-s chair stand test, 6MWT six-minute-walk-test, BI bioelectrical impedance, DXA whole-body dual-energy x-ray absorptiometry, EORTC-
QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, HADS Hospital Anxiety and Depression Scale, MDASI M.D.
Anderson Symptom Inventory, PRPS patient-reported performance status
Mikkelsen et al. BMC Cancer  (2018) 18:934 Page 7 of 11
Change over time in ordinal categorical values will
be evaluated by a trend test using logistic regression.
Within-group and between-group differences in
continuous-level data will be performed using inde-
pendent T-tests. Overall and cancer specific survival
will be analyzed with the Kaplan-Meier method, compet-
ing risk and Cox regression analyses. The significance level
of all tests is set at p < 0.05 and analyses will be carried
out in R by the program’s statistician (AT).
Discussion
We have designed a randomized controlled trial to investi-
gate the effect of a multimodal exercise-based intervention
for older patients with advanced PC, BTC and LC under-
going first-line palliative treatment. The elements of
exercise in the PACE-Mobil-PBL intervention are de-
signed in accordance with Danish and international rec-
ommendations for exercise training in healthy
individuals and in patients with cancer [63–65]. Focus-
ing on older patients with advanced PC, BTC and LC,
several factors have been considered in targeting the
intervention, including age-related limitations and co-
morbidities. Due to the high incidence of cancer cach-
exia and sarcopenia among these patient groups, the
main priority of the exercise program lies on resistance
training, whereas high intensity cardiovascular training
that requires high energy consumption is avoided. With
the aim of avoiding inactivity, an individualized light to
moderate intensity home-based activity program based
on step counts will be developed for each participant.
The multimodal intervention also includes two individ-
ualized counseling sessions. The aim of the counseling
is to help participants to cope with their current situ-
ation in different life domains. The content related to
selected domains and questions in the counseling is in-
spired by the comprehensive geriatric assessment, and
by Danish recommendations for the basic palliative as-
sessment [66, 67]. As patients with advanced PC, BTC
and LC are at high risk of multiple debilitating symp-
toms and side effects during oncological treatment, such
as fatigue, anorexia, pain, respiratory problems and psy-
chological distress [68–70], counseling sessions will specif-
ically focus on optimizing participants’ symptom
management. The approach in guiding participants to
manage their symptoms and side effects is inspired by the
Integrated Approach to Symptom Management developed
by Larson et al. [71]. Information on sufficient nutrition
during the course of cancer treatment will be incorporated
as a mandatory element in the first counseling session,
and a protein supplement will be served to all participants
after all training sessions. Focus on nutrition is incorpo-
rated as nutritional status is recognized as an independent
predictor of cancer-related outcomes such as treatment
tolerance and mortality [72, 73]. Furthermore, evidence
suggests that malnutrition is highly prevalent in pa-
tients with cancer, particularly among older patients
with cancer [74].
In the PACE-Mobil-PBL intervention, motivation is
considered a key factor in engaging participants in exer-
cise training and symptom management, both short and
long term. The approach to participants in the nurse-led
counseling is inspired by the concept and techniques from
Motivational Interviewing [75]. Motivational Interviewing
is a collaborative and person-centered method that helps
people to resolve ambivalence, and to strengthen their
internal motivation needed for a behavior change.
Motivational Interviewing has been applied in various
settings, and has proven to be an effective counseling
strategy in life style changes among patients with cancer
[76]. Goal-setting is incorporated as an element in the
home-based activity program, as it is recognized as an
effective method to achieve behavioral changes, and to en-
hance motivation and self-efficacy [77].
With the aging population and expected increase in
cancer incidence, especially among older people, new
approaches of early rehabilitation are needed in order to
maintain physical function, independence and QoL in
older patients with advanced cancer. PACE-Mobil-PBL
has the potential to become a new model of early re-
habilitation for older patients with advanced PC, BTC
and LC. In the long term, it is our goal to investigate the
multimodal program’s effect among older patients with
various malignancies in order to map out the effects,
common features and differences across cancers, with an
overall focus on older patients with cancer.
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